Eledon Pharmaceuticals, Inc. Share Price
Equities
ELDN
US28617K1016
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.285 USD | +10.92% | +14.29% | +28.26% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 51.12M 4.07B |
---|---|---|---|---|---|
Net income 2024 * | -53M -4.22B | Net income 2025 * | -74M -5.89B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.42
x | P/E ratio 2025 * |
-2.29
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.57% |
Latest transcript on Eledon Pharmaceuticals, Inc.
1 day | +10.92% | ||
1 week | +14.29% | ||
Current month | +12.07% | ||
1 month | +16.02% | ||
3 months | +24.12% | ||
6 months | +46.12% | ||
Current year | +28.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 30/04/20 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 14/03/21 |
Steven N. Perrin
PSD | President | 59 | 13/09/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 30/04/17 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 13/09/20 |
John S. McBride
BRD | Director/Board Member | 72 | 30/04/17 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 2.27 | +10.20% | 158 413 |
26/04/24 | 2.06 | +1.98% | 81,544 |
25/04/24 | 2.02 | +2.54% | 67,382 |
24/04/24 | 1.97 | -8.80% | 100,805 |
23/04/24 | 2.16 | +6.93% | 190,023 |
Delayed Quote Nasdaq, April 29, 2024 at 06:40 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.26% | 51.12M | |
-2.51% | 103B | |
+1.85% | 95.28B | |
+1.46% | 22.15B | |
-15.75% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.86% | 16.05B | |
+5.45% | 13.68B | |
+34.88% | 12.17B |
- Stock Market
- Equities
- ELDN Stock